Bristol-Myers scoops Inhibitex for $2.5bn
This article was originally published in Scrip
Executive Summary
As predicted in the latest Scrip Pharma Trends, the hepatitis C space is hotting up further. Less than two months after Gilead Sciences offered an eye-watering $11 billion to buy Pharmasset, Bristol-Myers Squibb is acquiring Inhibitex for $26 a share, valuing the company at $2.5 billion. The offer represents a 163% premium to the $9.87 Inhibitex share price at the close of markets on 6 January. The Inhibitex board has agreed to not solicit any competing offers for its company.
You may also be interested in...
Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.
MoCRA Registrants Encouraged By Glimpse Into Cosmetics Direct Portal, But Apprehensions Remain
Jessica O’Connell, partner at Covington & Burling, is getting questions from clients about the electronic system the FDA plans to launch in coming weeks for cosmetics manufacturers to register facilities and list products as required by new cosmetics regulations. It remains to be seen how hard the 29 December 2023 deadline will be for companies to get their information submitted.
Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope
Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.